- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
AML | Clinical
Expert Discusses Need for a More Targeted Approach in Acute Myeloid Leukemia
October 15, 2021
In an interview with Targeted Oncology, Alice S. Mims, MD, discussed targeting biomarkers in acute myeloid leukemia, and upfront disease management.
Genetic Testing for Actionable Mutations in Newly-Diagnosed AML
October 15, 2021
Alice S. Mims, MD a hematologist at The Ohio State University Comprehensive Cancer Center, discusses testing and actionable mutations in newly diagnosed acute myeloid leukemia.
FLAG-IDA and Venetoclax Produce Durable Remissions in Newly Diagnosed AML
September 09, 2021
The combination of fludarabine, cytarabine, idarubicin and G-CSF and venetoclax produces durable responses and has an acceptable safety profile in patients with newly diagnosed acute myeloid leukemia.
Leukemia Awareness Month: Changing the Future of AML through Precision Medicine
September 08, 2021
Gwen Nichols, MD, reviews the evolving landscape of acute myeloid leukemia for Leukemia Awareness Month.
Determining the Outcomes of TTI-622 With Azacitidine for TP53-Mutant AML
September 06, 2021
Cancer research sites across the United States are evaluating the use of TTI-622 plus azacitidine in patients with T53-mutated acute myeloid leukemia.
Iomab-B Shows Early Promise Versus Standard Therapy in Elderly R/R AML
September 03, 2021
In an interview with Targeted Oncology™, Rajneesh Nath, MD, discussed the need for novel treatment for elderly patients with relapsed/refractory AML and how the SIERRA trial is designed to help.
Ivosidenib Plus Azacitidine Shows EFS Benefit in IDH1+ Acute Myeloid Leukemia
August 02, 2021
Treatment with ivosidenib tablets in combination with azacitidine led to improvement in event-free survival in patients with previously untreated IDH1-mutated acute myeloid leukemia, meeting the primary end point of the phase 3 AGILE study.
Unmet Medical Needs Remain in the AML Treatment Landscape
July 30, 2021
Marcin Kortylewski, PhD, discusses the need for additional strategies for the treatment of acute myeloid leukemia.
Eprenetapopt With Azacitidine Demonstrates Efficacy in TP53-Positive MDS and AML
July 23, 2021
Eprenetapop combined with azacitidine has shown positive efficacy as post-transplant maintenance therapy for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia treated in a phase 2 study.
FDA Lifts Partial Clinical from Study of RVU120 in Relapsed/Refractory AML and MDS
July 15, 2021
The FDA has lifted its partial clinical hold on a phase 1B study of RVU120, which is an investigation of the agent for the treatment of patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.